Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis.
|
31646807 |
2020 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analogous to mesothelioma and ovarian carcinoma, a significant increase of MSLN was detected in plasma from patients with hydrosalpinx.
|
31222072 |
2019 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although there is a considerable overlap in OC and BC immunohistochemical profiles, BC usually stain positive for GCDFP-15 and negative for vimentine, PAX8, and WT1, and OC often stain positive for CK7, PAX8, WT1, and to mesothelin.
|
29680194 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
ONCOS-102 has already been found to be well tolerated and efficacious against some types of treatment-refractory tumors, including mesothelin-positive ovarian cancer (NCT01598129).
|
29797583 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody.
|
29462558 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data support further investigation of CARMA-hMeso as a potential treatment for ovarian cancer and other mesothelin-expressing cancers.
|
29334771 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expert commentary: Based on existing evidences the authors advocate that agents targeting MUC16-MSLN may add to the therapeutic armamentarium directed to abrogate peritoneal homing of ovarian cancer.
|
29241375 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein, we investigated the antitumor efficacy of the mesothelin-targeting antibody-drug conjugate (ADC) anetumab ravtansine as a novel treatment option for ovarian cancer in monotherapy and in combination with the antitumor agents pegylated liposomal doxorubicin (PLD), carboplatin, copanlisib and bevacizumab.
|
30344925 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, Mesothelin-GITR-CD3 CAR-T cells also killed mesothelin-positive ovarian cancer cell lines, and pancreatic cancer cells.
|
29772559 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MSLN is prevalent in mesothelia tissues but is expressed in several human cancers, such as OC, pancreatic cancer, mesothelioma, and lung cancer.
|
29184420 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mesothelin is a promising target for immune-based therapy, specifically for mesothelioma and pancreatic and ovarian cancers that have high levels of mesothelin expression.
|
26973126 |
2016 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we developed a novel cell-based vaccine, Meso-VAX, to generate mesothelin antigen-specific immune responses and immunotherapy against ovarian cancer.
|
26262583 |
2016 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mesothelin (MSLN) is overexpressed in many human tumors, including mesotheliomas and pancreatic and ovarian carcinomas.
|
27422997 |
2016 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We developed a novel immunotherapeutic agent that links a single-chain antibody variable fragment (scFv) targeting mesothelin (MSLN), which is overexpressed on ovarian cancer and mesothelioma cells, to Mycobacterium tuberculosis (MTB) heat shock protein 70 (Hsp70), which is a potent immune activator that stimulates monocytes and DCs, enhances DC aggregation and maturation and improves cross-priming of T cells mediated by DCs.
|
24565018 |
2014 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
N-ERC/mesothelin is a soluble protein and has been reported to be a diagnostic serum marker of mesothelioma and ovarian cancer.
|
24146039 |
2014 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mesothelin, a glycosylphosphatidylinositol (GPI) anchored cell surface protein, is a potential target for antibody-based cancer therapy due to its high expression in mesothelioma, ovarian cancer, pancreatic cancer, cholangiocarcinoma and other cancers.
|
22721387 |
2013 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Blocking the MSLN-related pathway could be a potential strategy for inhibiting the growth of ovarian cancer.
|
21999204 |
2012 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
We further show that in vitro sensitization of peripheral blood mononuclear cells in the presence of either mitomycin-treated OvC cells whose TGF-β1 gene was silenced or in vitro matured dendritic cells that had been pulsed with homogenates from OvC cells with silenced TGF-β1 generated a stronger Th1/Tc1 immune response to the respective wild-type OvC and also to the OvC antigens mesothelin and HE4 as measured by ELIspot assays.
|
22421944 |
2012 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to explore the therapeutic utility of a mesothelin promoter-based CRAd in a murine model of ovarian cancer, using noninvasive in vivo imaging.
|
18519792 |
2008 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ERC/mesothelin is expressed on the normal mesothelium and some cancers such as mesothelioma or ovarian carcinoma.
|
18328258 |
2008 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the current study, we utilized a DNA vaccine encoding human mesothelin (pcDNA3-Hmeso) to treat C57BL/6 mice challenged with luciferase-expressing, Hmeso-expressing ovarian cancer cell line, Defb29 Vegf-luc/Hmeso.
|
17581599 |
2007 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, mesothelin represents a potential target antigen for ovarian cancer vaccine development.
|
16930783 |
2007 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, MSLN is an attractive candidate for transcriptional and transductional targeting in the context of ovarian cancer gene therapy.
|
15526007 |
2005 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The identification of novel CTL agonist epitopes supports and extends observations that mesothelin is a potential target for immunotherapy of pancreatic and ovarian cancers, as well as mesotheliomas.
|
16144939 |
2005 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
CTD_human |
Using an online SAGE database (http://www.ncbi.nlm.gov/SAGE), we found the tag for mesothelin to be consistently present in the mesothelioma, ovarian cancer, and pancreatic cancer libraries but not in normal pancreas libraries.
|
11751476 |
2001 |